Data Year:

For its 2025 fiscal year, SOTERA HEALTH CO, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Business Services industry
Michael P. Rutz
President of Sterigenics
Total Compensation $2,180,029 View details Pay Rank By Title In Business Services industry #83 View more
Michael B. Petras Jr.
Chairman and CEO
Total Compensation $10,656,063 View details Pay Rank By Title In Business Services industry #171 View more
Alexander Dimitrief
Former SVP and General Counsel
Total Compensation $2,459,612 View details Pay Rank By Title In Business Services industry #37 View more
Jonathan Lyons
SVP, CFO
Total Compensation $3,086,383 View details Pay Rank By Title In Business Services industry #256 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at SOTERA HEALTH CO as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. SOTERA HEALTH CO income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. SOTERA HEALTH CO annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Michael P. Rutz
President of Sterigenics
Total Cash $820,250 Equity $1,341,266 Other $18,513 $2,180,029
Michael B. Petras Jr.
Chairman and CEO
Total Cash $2,615,589 Equity $8,022,400 Other $18,074 $10,656,063
Alexander Dimitrief
Former SVP and General Counsel
Total Cash $909,000 Equity $1,547,623 Other $2,989 $2,459,612
Jonathan Lyons
SVP, CFO
Total Cash $981,120 Equity $2,087,272 Other $17,991 $3,086,383
For its 2025 fiscal year, SOTERA HEALTH CO, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Michael B. Petras Jr. CEO Pay $10,656,063 Median Employee Pay $82,784 CEO Pay Ratio 129:1
For its 2024 fiscal year, SOTERA HEALTH CO, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Ann R. Klee Total Cash $322,497
Christopher Simon Total Cash $33,261
Constantine S. Mihas Total Cash $304,997
David A. Donnini Total Cash $278,068
David E. Wheadon, M.D. Total Cash $309,997
James C. Neary Total Cash $319,997
Karen A. Flynn Total Cash $306,446
Robert B. Knauss Total Cash $299,997
Ruoxi Chen Total Cash $302,497
Sean L. Cunningham Total Cash $302,497
Vincent K. Petrella Total Cash $324,997
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.